Form 4: Liquidia CEO Roger Jeffs Executes Stock Sale Plan

Liquidia Corporation CEO Roger Jeffs sold 75,000 shares of common stock over three days in May 2026 under a pre-arranged 10b5-1 trading plan.

Summary

• CEO Roger Jeffs sold a total of 75,000 shares of Liquidia Corp (LQDA) common stock between May 18 and May 20, 2026.
• The sales were executed in three equal tranches of 25,000 shares each.
• The transactions were conducted at volume-weighted average prices of $56.77, $58.65, and $61.30 per share.
• The sales were performed pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.
• Following these transactions, the reporting person retains beneficial ownership of 1,123,095 shares held through Serendipity BioPharma LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and do not indicate a change in the CEO's confidence in the company's strategic direction.

Positives

• The sales were executed under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.
• The CEO maintains a significant remaining equity stake in the company, signaling continued alignment with shareholder interests.

Negatives

• The sale of 75,000 shares represents a reduction in the CEO's direct and indirect holdings.

Risks

• Insider selling can sometimes be perceived negatively by the market, potentially creating short-term downward pressure on the stock price.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine in the biopharmaceutical sector and generally reflect personal financial planning rather than a change in outlook regarding the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at companies like United Therapeutics or MannKind to manage equity compensation while maintaining regulatory compliance.

Related Party Transactions

• The reporting person is the trustee of the Roger A. Jeffs Living Trust and a manager of Serendipity BioPharma LLC, which hold the reported securities.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event for the CEO rather than a signal of operational distress.

Next Steps

• Continued monitoring of future Form 4 filings to track any further sales under the existing 10b5-1 plan.

Key Dates

Keywords

Liquidia, LQDA, Insider Trading, Form 4, Roger Jeffs, Biopharma, 10b5-1